Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM)

Author(s):  
Sibylle Neuhoff ◽  
Lu Gaohua ◽  
Howard Burt ◽  
Masoud Jamei ◽  
Linzhong Li ◽  
...  
Keyword(s):  
1977 ◽  
Vol 16 (03) ◽  
pp. 100-103 ◽  
Author(s):  
C. Schümichen ◽  
J. Waiden ◽  
G. Hoffmann

SummaryThe kinetic data of two different 99mTc-Sn-pyrophosphate compounds (compound A and B) were evaluated in non-adult rats. Only compound A concentrated in bone. Both compounds dispersed rapidly in the intravascular as well as the extravascular space. The plasma protein bond of both compounds increased with time after injection and impaired both the renal clearance of both compounds and the bone clearance of compound A. The renal clearance of both compounds was somewhat above that of 5 1Cr-EDTA. It is concluded that compound A and B is mainly excreted by glomerular filtration. About one fourth of the glomerular filtrate of compound B is reabsorbed and accumulated by the tubular cells.


Author(s):  
Stephanie E. Reuter ◽  
Hayley B. Schultz ◽  
Michael B. Ward ◽  
Crystal L. Grant ◽  
Gemma M. Paech ◽  
...  

2021 ◽  
Vol 11 (16) ◽  
pp. 7187
Author(s):  
Peter V. Hauser ◽  
Hsiao-Min Chang ◽  
Norimoto Yanagawa ◽  
Morgan Hamon

The kidneys are vital organs performing several essential functions. Their primary function is the filtration of blood and the removal of metabolic waste products as well as fluid homeostasis. Renal filtration is the main pathway for drug removal, highlighting the importance of this organ to the growing field of nanomedicine. The kidneys (i) have a key role in the transport and clearance of nanoparticles (NPs), (ii) are exposed to potential NPs’ toxicity, and (iii) are the targets of diseases that nanomedicine can study, detect, and treat. In this review, we aim to summarize the latest research on kidney-nanoparticle interaction. We first give a brief overview of the kidney’s anatomy and renal filtration, describe how nanoparticle characteristics influence their renal clearance, and the approaches taken to image and treat the kidney, including drug delivery and tissue engineering. Finally, we discuss the future and some of the challenges faced by nanomedicine.


1988 ◽  
Vol 15 (1) ◽  
pp. 57-65 ◽  
Author(s):  
A. Hedman ◽  
Y. Adan-Abdi ◽  
G. Alvan ◽  
B. Strandvik ◽  
A. Arvidsson

2021 ◽  
Vol 49 (5) ◽  
pp. 030006052110155
Author(s):  
Brian W Johnston ◽  
David Perry ◽  
Martyn Habgood ◽  
Miland Joshi ◽  
Anton Krige

Objective Augmented renal clearance (ARC) is associated with sub-therapeutic antibiotic, anti-epileptic, and anticoagulant serum concentrations leading to adverse patient outcomes. We aimed to describe the prevalence and associated risk factors for ARC development in a large, single-centre cohort in the United Kingdom. Methods We conducted a retrospective observational study of critically unwell patients admitted to intensive care between 2014 and 2016. Urinary creatinine clearance was used to determine the ARC prevalence during the first 7 days of admission. Repeated measures logistic regression was used to determine risk factors for ARC development. Results The ARC prevalence was 47.0% (95% confidence interval [95%CI]: 44.3%–49.7%). Age, sex, Acute Physiology and Chronic Health Evaluation (APACHE) II score, and sepsis diagnosis were significantly associated with ARC. ARC was more prevalent in younger vs. older (odds ratio [OR] 0.95 [95%CI: 0.94–0.96]), male vs. female (OR 0.32 [95%CI: 0.26–0.40]) patients with lower vs. higher APACHE II scores (OR 0.94 [95%CI: 0.92–0.96]). Conclusions This patient group probably remains unknown to many clinicians because measuring urinary creatinine clearance is not usually indicated in this group. Clinicians should be aware of the ARC risk in this group and consider measurement of urinary creatinine clearance.


2018 ◽  
Vol 46 (1) ◽  
pp. 672-672
Author(s):  
Lauren Flieller ◽  
Nicholas Farina ◽  
Michael Heung ◽  
Lenar Yessayan ◽  
Melissa Pleva

Sign in / Sign up

Export Citation Format

Share Document